Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

Study Overview
=================
Brief Summary
-----------------
This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease). Participants will continue their normal care and will not get any treatment other than those the study doctor has prescribed.

Official Title
-----------------
Prevalence of Systemic Inflammation in Patients With Atherosclerotic Cardiovascular Disease and Heart Failure

Conditions
-----------------
Chronic Kidney Disease, Cardiovascular Risk, Heart Failure

Intervention / Treatment
-----------------
* Other: No treatment given


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study. Age 18 years or above at the time of signing the informed consent. Presence of ASCVD (atherosclerotic cardiovascular disease) and/or HF (heart failure) Presence of serum creatinine in the medical chart within 24 months prior to signing of informed consent (for ASCVD patients only). Exclusion criteria: Previous participation in this study. Participation is defined as having given informed consent in this study. Current participation (i.e., signed informed consent) in any other interventional clinical study. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization). Clinical evidence, or suspicion of, active infection within the last 60 days. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD)<br>electronic case report form (eGFR) below 60 ml/min/1.73m^2 | Other: No treatment given<br>* No treatment given<br>|
| ASCVD without CKD<br>eGFR greater than or equal to 60 ml/min/1.73m^2 | Other: No treatment given<br>* No treatment given<br>|
| HF with preserved ejection fraction (HFpEF) or HF with mildly reduced ejection fraction (HFmrEF)<br> | Other: No treatment given<br>* No treatment given<br>|
| Heart failure (HF) with reduced ejection fraction (HFrEF)<br> | Other: No treatment given<br>* No treatment given<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| High sensitivity C-reactive protein (hsCRP) greater than or equal to 2 mg/L (yes/ no) | Count of patient | At visit (day 0) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interleukin 6 (IL-6) | pg/ml | At visit (day 0) | 
| N-terminal prohormone of brain natriuretic peptide (NT-proBNP) | pg/ml | At visit (day 0) |